Prognostication with Thyroid GuidePx in the context of tall cell variants.

Autor: Craig S; Department of Surgery, Illawarra Shoalhaven Local Health District, Warrawong, New South Wales, Australia; Graduate School of Medicine, University of Wollongong, Warrawong, New South Wales, Australia., Stretch C; Department of Oncology, Cumming School of Medicine, University of Calgary, AB, Canada; Qualisure Diagnostics Inc, Calgary, AB, Canada. Electronic address: https://twitter.com/CynStre., Yeo C; Department of Surgery, Cumming School of Medicine, University of Calgary, AB, Canada., Fan J; Qualisure Diagnostics Inc, Calgary, AB, Canada., Pedersen H; Qualisure Diagnostics Inc, Calgary, AB, Canada., Park YJ; Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Republic of Korea; Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Republic of Korea., Harvey A; Department of Surgery, Cumming School of Medicine, University of Calgary, AB, Canada., Bathe OF; Department of Oncology, Cumming School of Medicine, University of Calgary, AB, Canada; Qualisure Diagnostics Inc, Calgary, AB, Canada; Department of Surgery, Cumming School of Medicine, University of Calgary, AB, Canada. Electronic address: bathe@ucalgary.ca.
Jazyk: angličtina
Zdroj: Surgery [Surgery] 2025 Jan; Vol. 177, pp. 108882. Date of Electronic Publication: 2024 Oct 28.
DOI: 10.1016/j.surg.2024.06.080
Abstrakt: Background: The tall cell variant of papillary thyroid cancer generally has a worse prognosis compared with the classical variant. Thyroid GuidePx is a genomic classifier capable of classifying papillary thyroid cancer into 3 molecular subtypes using fine-needle aspirate. Type 1 and 2 have low recurrence rates, particularly in early tumors (1-4 cm and N0). Type 3 is characterized by aggressive biology and high recurrence rates regardless of size and lymph node status. The study examines the interaction of tall cell variant histology with Thyroid GuidePx risk stratification.
Methods: Gene expression data from 736 patients (The Cancer Genome Atlas, Canada, and South Korea), were submitted to the Thyroid GuidePx classifier. Results across the 3 molecular subtypes were further dichotomized into "early" papillary thyroid cancer (tumor size 1-4 cm and N0) (n = 369; 51%) or "advanced" papillary thyroid cancer (n = 359; 49%). Structural recurrence was the primary outcome measure in our analysis. Transcriptomic and genomic analysis was conducted to explore what biological differences could account for clinical differences between tall cell variant and non- tall cell variants.
Results: Thyroid GuidePx identified 369 early papillary thyroid cancers: 129 (35%) type 1, 168 (45.5%) type 2, and 72 (19.5%) type 3. The recurrence rates for early type 1, type 2, and type 3 papillary thyroid cancers were 3.9%, 1.9%, and 19.4%, respectively. There were no type 1 tall cell variants. In type 2 papillary thyroid cancers, the incidence of tall cell variant was greater in advanced than early papillary thyroid cancers (10.2% vs 4.2%, P = .04). Notably, none of the 7 early type 2 tall cell variants recurred. In type 3 papillary thyroid cancers, the prevalence of tall cell variants was similar in early and advanced tumors (10% vs 9%, NS). When compared with non-tall cell variants, early type 3 tall cell variants trended toward greater recurrence (28.6% vs 18.5%, not significant) whereas advanced type 3 tall cell variants had a significantly greater recurrence rate (50% vs 28.6%, P = .01). Biologically, type 3 tall cell variants had had a pronounced enrichment in cell proliferation, epithelial-mesenchymal transition, invasion, and inflammation.
Conclusion: Thyroid GuidePx reliably identifies a low-risk subgroup (early type 1 and early type 2 papillary thyroid cancers) for which conservative procedures would be appropriate. Tall cell variants in this subgroup are uncommon (1.2%), and none of the tall cell variants in this subgroup recurred. Type 3 papillary thyroid cancers have greater recurrence rates in both early and advanced papillary thyroid cancers. Tall cell variant appears to further increase recurrence in this subgroup.
Competing Interests: Conflict of Interest/Disclosure The intellectual property behind Thyroid GuidePx is owned by Qualisure Diagnostics Inc. S.C., C.S., and O.B. own shares in Qualisure Diagnostics, Inc. The other authors have no conflicts of interest to disclose.
(Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: